“The #1 Tech Opportunity of the Decade”

On February 8th, Luke Lango is making his biggest call of 2023. He’s recommending technology (that you’ve likely never heard of) that could help 122 million people… And mint up to $3 trillion in wealth.

Wed, February 8 at 8:00PM ET
 
 
 
 

Why Altimmune Stock Is Skyrocketing Today

Altimmune stock (NASDAQ:ALT) stock went gangbusters on Wednesday as the company has been making a lot of recent moves that have been paying dividends.

Altimune Stock
Source: iStock

Altimmune’s vaccine candidate also proved to elicit a considerable T cell immune response when compared to Fluzone, which is a licensed injected influenza vaccine. The company has other irons in the fire as its Phase 1-stage HepTcell has been successful so far.

The product is designed to treat the hepatitis B virus (HBC) infection. Altimmune also has an anthrax vaccine, as well as a cancer immunotherapeutic product in Oncosyn that it is developing at the moment.

The company also announced and completed a 1:30 reverse split of its common shares last week. At the end of June, Altimmune had $4.2 million in quick assets, while its operations amassed $3.2 million during the company’s first half of the fiscal year.

ALT stock was skyrocketing about 285.5% on Wednesday following all of the company’s positive moves over the last couple of weeks. Shares tapered slightly after the bell, declining 2.2%.


Article printed from InvestorPlace Media, https://investorplace.com/2018/09/altimmune-stock-alt/.

©2023 InvestorPlace Media, LLC